# BBO-11818 in Adult Subjects With KRAS Mutant Cancer

> **NCT06917079** · PHASE1 · RECRUITING · sponsor: **TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)** · enrollment: 387 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- NSCLC
- PDAC - Pancreatic Ductal Adenocarcinoma
- CRC (Colorectal Cancer)
- Metastatic Non-Small Lung Cell Cancer
- Metastatic Colorectal Cancer (CRC)
- KRAS G12A
- KRAS G12C
- KRAS G12D
- KRAS G12S
- KRAS G12V
- Metastatic Pancreatic Ductal Adenocarcinoma
- Advanced Lung Carcinoma
- Solid Tumor, Adult

## Interventions

- **DRUG:** BBO-11818
- **DRUG:** Pembrolizumab
- **DRUG:** Platinum chemotherapy (cisplatin or carboplatin)
- **DRUG:** Pemetrexed
- **DRUG:** Cetuximab
- **DRUG:** FOLFOX
- **DRUG:** NALIRIFOX
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT06917079
- **Lead sponsor:** TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2027-08
- **Final completion:** 2029-09
- **Target enrollment:** 387 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917079, "BBO-11818 in Adult Subjects With KRAS Mutant Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06917079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*